FDA — authorised 23 August 2024
- Application: BLA761298
- Marketing authorisation holder: AMGEN INC
- Status: approved
🇺🇸 PAVBLU in United States
FDA authorised PAVBLU on 23 August 2024
Marketing authorisation
PAVBLU in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is PAVBLU approved in United States?
Yes. FDA authorised it on 23 August 2024.
Who is the marketing authorisation holder for PAVBLU in United States?
AMGEN INC holds the US marketing authorisation.